Inhibition of PERK-mediated unfolded protein response acts as a switch for reversal of residual senescence and as senolytic therapy in glioblastoma
- 18 July 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 26 (11) , 2027-2043
Abstract
Background: Glioblastoma due to recurrence is clinically challenging with 10–15 months overall survival. Previously we showed that therapy-induced senescence (TIS) in glioblastoma reverses causing recurrence. Here, we aim to delineate the TIS reversal mechanism for potential therapeutic intervention to prevent glioblastoma (GBM) recurrence. Methods: Residual senescent (RS) and end of residual senescence (ERS) cells were captured from GBM patient-derived primary-cultures and cell lines mimicking clinical scenarios. RNA-sequencing, transcript/protein validations, knock-down/inhibitor studies, ChIP RT-PCR, biochemical assays, and IHCs were performed for the mechanistics of TIS reversal. In vivo validations were conducted in GBM orthotopic mouse model. Results: Transcriptome analysis showed co-expression of endoplasmic reticulum (ER) stress-unfolded protein response (UPR) and senescence-associated secretory phenotype (SASP) with TIS induction and reversal. Robust SASP production and secretion by RS cells could induce senescence, Reactive oxygen specis (ROS), DNA damage, and ER stress in paracrine fashion independent of radiation. Neutralization of most significantly enriched cytokine from RS-secretome IL1β, suppressed SASP, and delayed senescence reversal. Mechanistically, with SASP and massive protein accumulation in ER, RS cells displayed stressed ER morphology, upregulated ER stress markers, and PERK pathway activation via peIF2α-ATF4-CHOP which was spontaneously resolved in ERS. ChIP RT-PCR showed CHOP occupancy at CXCL8/IL8, CDKN1A/p21, and BCL2L1/BCLXL aiding survival. PERK knockdown/inhibition with GSK2606414 in combination with radiation led to sustained ER stress and senescence without SASP. PERKi in RS functioned as senolytic via apoptosis and prevented recurrence in vitro and in vivo ameliorating overall survival. Conclusion: We demonstrate that PERK-mediated UPR regulates senescence reversal and its inhibition can be exploited as a potential seno-therapeutic option in glioblastoma.Keywords
Funding Information
- Department of Science and Technology (EMR/2017/004994)
- the Department of Biotechnology (BT/PR13863/MED/122/6/2016)
- Department of Atomic Energy (1/3(7)/2020/TMC/R&D-II/8823)
- Department of Atomic Energy (1/3(6)/2020/TMC/R&D-II/3805)
This publication has 46 references indexed in Scilit:
- ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastomaRadiotherapy and Oncology, 2023
- Substrate stiffness regulates the recurrent glioblastoma cell morphology and aggressivenessMatrix Biology, 2022
- Targeting senescence as an anticancer therapyMolecular Oncology, 2022
- Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescenceCancer Letters, 2020
- Inhibition of novel GCN5–ATM axis restricts the onset of acquired drug resistance in leukemiaInternational Journal of Cancer, 2018
- The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastomaBiochemical Pharmacology, 2016
- Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from SenescenceNeoplasia, 2015
- Isolation of Endoplasmic Reticulum, Mitochondria, and Mitochondria‐Associated Membrane and Detergent Resistant Membrane Fractions from Transfected Cells and from Human Cytomegalovirus‐Infected Primary FibroblastsCurrent Protocols in Cell Biology, 2015
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapyNature, 2013
- Senescence: a new weapon for cancer therapyTrends in Cell Biology, 2012